Paraplegia News and Research RSS Feed - Paraplegia News and Research

Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.

Study shows spinal stimulation therapy may have potential to change prognosis of people with paralysis

Four people with paraplegia are able to voluntarily move previously paralyzed muscles as a result of a novel therapy that involves electrical stimulation of the spinal cord, according to a study funded in part by the National Institutes of Health and the Christopher & Dana Reeve Foundation. [More]
UC San Diego researchers uncover causes for hereditary spastic paraplegia

UC San Diego researchers uncover causes for hereditary spastic paraplegia

In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features. [More]

ARGO Medical partners with YASKAWA for global expansion of ReWalk exoskeleton device

ARGO Medical Technologies has partnered with innovative robotics experts YASKAWA Electric Corporation as it continues the global expansion of its ReWalk exoskeleton device which enables individuals with lower limb disabilities such as paraplegia to walk. [More]
Journal of Spinal Cord Medicine's July issue focuses on assistive technology for spinal cord injury

Journal of Spinal Cord Medicine's July issue focuses on assistive technology for spinal cord injury

The July issue of the Journal of Spinal Cord Medicine focuses on, "Advances in Technology for People with Spinal Cord Injury." Guest Editor Rory Cooper, PhD, is a member of the journal's Editorial Board. Dr. Cooper is the FISA/PVA Endowed Chair and a Distinguished Professor of the Department of Rehabilitation Science and Technology, School of Health and Rehabilitation Sciences, University of Pittsburgh. [More]

ARGO launches ReWalk Rehabilitation 2.0 system

ARGO Medical Technologies has unveiled the newest generation of its ReWalk Rehabilitation exoskeleton that enables individuals with spinal cord injuries the ability to walk again. [More]
Bionic devices: an interview with Dr Rylie Green

Bionic devices: an interview with Dr Rylie Green

Bionic devices are implants which replace biological functions which have been lost due to nerve damage. They use electrical signals to stimulate the remaining nerve cells following disease or injury. Although the term bionic was only coined in the late 1950s, the earliest bionic devices were cardiac pacemakers, developed in the early 1900s. However the first commercial implantable units were not available until the 1950s. [More]
University of Tübingen heads Neuromics consortium

University of Tübingen heads Neuromics consortium

Work has begun on Neuromics, a major project headed by Tübingen's Professor Olaf Riess; the project beat out ten other first-class applications to attain €12m euros in EU funding over five years. [More]

Powered exoskeleton provides more independence to people with severe spinal cord injuries

The dream of regaining the ability to stand up and walk has come closer to reality for people paralyzed below the waist who thought they would never take another step. [More]
Neuralstem prices registered direct offering of 7,000,000 shares of common stock

Neuralstem prices registered direct offering of 7,000,000 shares of common stock

Neuralstem, Inc. today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. [More]
Q Therapeutics licenses Neuralstem's Spinal Cord Delivery Platform and Floating Cannula

Q Therapeutics licenses Neuralstem's Spinal Cord Delivery Platform and Floating Cannula

Neuralstem, Inc. announced that it has granted the first licenses for use of its Spinal Cord Delivery Platform and Floating Cannula, for delivering therapeutic agents to the spinal cord, to Salt Lake City-based Q Therapeutics. [More]
Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Kessler Foundation has released preliminary research findings from its clinical study of the wearable robotic exoskeletal device, Ekso. Gail Forrest, PhD, assistant director of Human Performance and Engineering Research, presented the Ekso research data on September 3, at the meeting of the Academy of Spinal Cord Injury Professionals at the Rio Suites in Las Vegas. Dr. Forrest directs mobility research at the Foundation, including activity-based locomotor therapy, functional electrical stimulation, and treadmill training with the LokomatPro v6, as well as Ekso. [More]

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use. [More]

Exoskeleton technology now available to take home

Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use. Claire demonstrated her personal ReWalk™ at the annual International Spinal Cord Society (ISCoS) meeting held at the Queen Elizabeth II Conference Center. [More]
Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Neuralstem completes NSI-566 Phase I trial on amyotrophic lateral sclerosis

Neuralstem, Inc. announced the completion of the Phase I trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), with the eighteenth patient treated. [More]
Advanced understanding of neurodegenerative diseases achieved by Trophos

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC. [More]
Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem, Inc. announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). [More]

Stem Cells reports results of Neuralstem ALS Phase I trial

Neuralstem, Inc. announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cells, on March 13th. [More]

Ekso Bionics, Kessler Foundation partner to test commercial robotic exoskeleton

On Monday, Kessler Foundation became the second rehabilitation research center in the U.S. to implement Ekso, a wearable, robotic battery-powered exoskeleton that allows wheelchair users with lower-extremity weakness to stand and walk. [More]
Intraoperative monitoring of spinal cord may help prevent paralysis

Intraoperative monitoring of spinal cord may help prevent paralysis

The American Academy of Neurology is issuing an updated guideline that recommends monitoring the spinal cord during spinal surgery and certain chest surgeries to help prevent paralysis, or loss of muscle function, related to the surgeries. [More]

Neuralstem announces registered direct placement of 5,200,000 shares of common stock

Neuralstem, Inc. announced today that it has entered into agreements with certain institutional and accredited investors for a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share for aggregate gross proceeds of $5,200,000. [More]